Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477186 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 185
- Enrollment target
NCT05477186 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 185 participants.
The verdict
NCT05477186, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 185 participants
- Enrollment target
Study Summary
Prevention of COVID-19 caused by SARS-CoV-2.
Interventions
- BIOLOGICAL CV0501 (3 μg)
- BIOLOGICAL CV0501 (6 μg)
- BIOLOGICAL CV0501 (12 μg)
- BIOLOGICAL CV0501 (25 μg)
- BIOLOGICAL CV0501 (50 μg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2023-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05477186
The ClinicalTrials.gov registry entry for NCT05477186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CV0501 (3 μg) is the first listed.
NCT05477186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05477186 about?
NCT05477186 is a clinical study titled "Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old". Prevention of COVID-19 caused by SARS-CoV-2.
What is the current status of trial NCT05477186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 185 participants. The study started on 2022-08-12. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT05477186?
The interventions under investigation include: CV0501 (3 μg) (BIOLOGICAL), CV0501 (6 μg) (BIOLOGICAL), CV0501 (12 μg) (BIOLOGICAL), CV0501 (25 μg) (BIOLOGICAL), CV0501 (50 μg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05477186?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.